-
公开(公告)号：EP3002298A1
公开(公告)日：2016-04-06
申请号：EP15189714.7
申请日：2008-11-21
IPC分类号： C07K16/36 , A61K39/395 , A61K45/06 , A61K39/00
CPC分类号： C07K16/36 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/32 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/624 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. Methods for making an anti-factor XI monoclonal antibody, or epitope-binding fragments, variants, or derivatives thereof, are also provided.
摘要翻译： 本发明涉及在不危及止血的情况下抑制血栓形成的组合物和方法。 组合物包括能够结合人FXI重链上的表位的抗因子XI单克隆抗体（aXIMab），特别是人类FXI重链的A3结构域。 组合物还包括单克隆抗体的表位结合片段，变体和衍生物，产生这些抗体组合物的细胞系和编码抗体氨基酸序列的分离的核酸分子。 本发明还包括在药学上可接受的载体中包含本发明的抗因子XI单克隆抗体或其表位结合片段，变体或衍生物的药物组合物。 本发明的方法包括将上述组合物施用于有需要的受试者，以抑制血栓形成，减少治疗血栓形成，治疗转移性癌症或治疗急性炎症反应所需的抗血栓形成剂量。 还提供了制备抗因子XI单克隆抗体或表位结合片段，变体或其衍生物的方法。
-
公开(公告)号：EP2222707A2
公开(公告)日：2010-09-01
申请号：EP08852770.0
申请日：2008-11-21
IPC分类号： C07K16/36
CPC分类号： C07K16/36 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2316/96 , C07K2317/24 , C07K2317/32 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/624 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. Methods for making an anti-factor XI monoclonal antibody, or epitope-binding fragments, variants, or derivatives thereof, are also provided.
-
公开(公告)号：EP2222707B1
公开(公告)日：2016-01-06
申请号：EP08852770.0
申请日：2008-11-21
IPC分类号： C07K16/36 , A61K39/395 , A61K39/00
CPC分类号： C07K16/36 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2316/96 , C07K2317/24 , C07K2317/32 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/624 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. Methods for making an anti-factor XI monoclonal antibody, or epitope-binding fragments, variants, or derivatives thereof, are also provided.
摘要翻译： 本发明涉及在不危及止血的情况下抑制血栓形成的组合物和方法。 组合物包括能够结合人FXI重链上的表位的抗因子XI单克隆抗体（aXIMab），特别是人类FXI重链的A3结构域。 组合物还包括单克隆抗体的表位结合片段，变体和衍生物，产生这些抗体组合物的细胞系和编码抗体氨基酸序列的分离的核酸分子。 本发明还包括在药学上可接受的载体中包含本发明的抗因子XI单克隆抗体或其表位结合片段，变体或衍生物的药物组合物。 本发明的方法包括将上述组合物施用于有需要的受试者，以抑制血栓形成，减少治疗血栓形成，治疗转移性癌症或治疗急性炎症反应所需的抗血栓形成剂量。 还提供了制备抗因子XI单克隆抗体或表位结合片段，变体或其衍生物的方法。
-
公开(公告)号：EP3002298B1
公开(公告)日：2019-08-28
申请号：EP15189714.7
申请日：2008-11-21
IPC分类号： C07K16/36 , A61K39/395 , A61K45/06 , A61K39/00
-
-
-
搜索结果
4 条记录 (耗时 0.02 秒)
